Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Hashimoto

Showing results (211-220 of 249) with videos related to

Pageof 25
Sort By:
JMIR Mental Health|May 30, 2024
Tablet-Based Cognitive and Eye Movement Measures as Accessible Tools for Schizophrenia Assessment: Multisite Usability StudyKentaro Morita, Kenichiro Miura, Atsuhito Toyomaki, et al.
The Lancet. Psychiatry|November 13, 2025
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trialsRichard S E Keefe, Philip D Harvey, Christoph U Correll, et al.
Bjpsych Open|June 3, 2022
Transdiagnostic comparisons of intellectual abilities and work outcome in patients with mental disorders: multicentre studyChika Sumiyoshi, Kazutaka Ohi, Haruo Fujino, et al.
Neuroimage. Clinical|December 5, 2017
The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjectsNaoki Hashimoto, Yoichi M Ito, Naohiro Okada, et al.
The International Journal of Neuropsychopharmacology|March 28, 2025
Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide studyShinichiro Ochi, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|November 4, 2016
Estimated cognitive decline in patients with schizophrenia: A multicenter studyHaruo Fujino, Chika Sumiyoshi, Yuka Yasuda, et al.
Neuropsychopharmacology Reports|December 2, 2021
Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation studyNorio Yasui-Furukori, Hiroyuki Muraoka, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|July 29, 2021
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Zoological Science|October 16, 2013
The diversity of shell matrix proteins: genome-wide investigation of the pearl oyster, Pinctada fucataHiroshi Miyamoto, Hirotoshi Endo, Naoki Hashimoto, et al.
BMC Psychiatry|May 28, 2024
The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter studyToshinori Nakamura, Ryuji Furihata, Naomi Hasegawa, et al.
Pageof 25

Showing results (211-220 of 249) with videos related to

Sort By:
Pageof 25
JMIR Mental Health|May 30, 2024
Tablet-Based Cognitive and Eye Movement Measures as Accessible Tools for Schizophrenia Assessment: Multisite Usability StudyKentaro Morita, Kenichiro Miura, Atsuhito Toyomaki, et al.
The Lancet. Psychiatry|November 13, 2025
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trialsRichard S E Keefe, Philip D Harvey, Christoph U Correll, et al.
Bjpsych Open|June 3, 2022
Transdiagnostic comparisons of intellectual abilities and work outcome in patients with mental disorders: multicentre studyChika Sumiyoshi, Kazutaka Ohi, Haruo Fujino, et al.
Neuroimage. Clinical|December 5, 2017
The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjectsNaoki Hashimoto, Yoichi M Ito, Naohiro Okada, et al.
The International Journal of Neuropsychopharmacology|March 28, 2025
Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide studyShinichiro Ochi, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Psychiatry and Clinical Neurosciences|November 4, 2016
Estimated cognitive decline in patients with schizophrenia: A multicenter studyHaruo Fujino, Chika Sumiyoshi, Yuka Yasuda, et al.
Neuropsychopharmacology Reports|December 2, 2021
Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation studyNorio Yasui-Furukori, Hiroyuki Muraoka, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|July 29, 2021
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Zoological Science|October 16, 2013
The diversity of shell matrix proteins: genome-wide investigation of the pearl oyster, Pinctada fucataHiroshi Miyamoto, Hirotoshi Endo, Naoki Hashimoto, et al.
BMC Psychiatry|May 28, 2024
The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter studyToshinori Nakamura, Ryuji Furihata, Naomi Hasegawa, et al.
Pageof 25